Probably not until after the second interim analysis, which is a long way off.
There’s no reason I know of to expect that the p-value at the second interim will meet the tiny alpha that’s customarily allocated to interim looks in cancer trials, even if one assumes that the HR will improve over time. Hence, the trial will likely proceed to a final analysis after the second interim, and investors will have plenty of time to get in after the second interim if the HR is disclosed and is impressive.
Market Data 
Markets 
AI
